C4 Therapeutics outlines milestones through 2028; cemsidomide Phase 2 trial on track for Q1 2026

C4 Therapeutics, Inc.

Cemsidomide Phase 2 MOMENTUM trial to begin Q1 2026; recommended Phase 2 dose 100 µg.
Phase 1b combination with elranatamab to start Q2 2026; potential accelerated approval path for 4L+ by end 2028.
Phase 1 data: 40% ORR at 75 µg, 53% ORR at 100 µg in heavily pretreated multiple myeloma patients.
Cash runway to end 2028 provides funding through key value inflection points including NDA submission.
Internal discovery strategy targeting inflammation and neurodegeneration; up to 3 IND applications by end 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.